Mark G. Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth A. Rowley,Eric P. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sarah E. Reese,Monica Dickerson,Allison L. Naleway,Jungmi Han,Deepika Konatham,Charlene McEvoy,Suchitra Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,Matthew E. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret H. Wondimu,Kempapura Murthy,Nimish R. Valvi,Julie Arndorfer,Bruce Fireman,Margaret M. Dunne,Peter Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H. Bozio,Sue Reynolds,Jill Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong

Abstract:Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ≥5 months after receipt of the second mRNA vaccine dose and that immunocompromised individuals receive a third primary dose.† A third dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine increases neutralizing antibody levels (4), and three recent studies from Israel have shown improved effectiveness of a third dose in preventing COVID-19 associated with infections with the SARS-CoV-2 B.1.617.2 (Delta) variant (5-7). Yet, data are limited on the real-world effectiveness of third doses of COVID-19 mRNA vaccine in the United States, especially since the SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in mid-December 2021. The VISION Network§ examined VE by analyzing 222,772 encounters from 383 emergency departments (EDs) and urgent care (UC) clinics and 87,904 hospitalizations from 259 hospitals among adults aged ≥18 years across 10 states from August 26, 2021¶ to January 5, 2022. Analyses were stratified by the period before and after the Omicron variant became the predominant strain (>50% of sequenced viruses) at each study site. During the period of Delta predominance across study sites in the United States (August-mid-December 2021), VE against laboratory-confirmed COVID-19-associated ED and UC encounters was 86% 14-179 days after dose 2, 76% ≥180 days after dose 2, and 94% ≥14 days after dose 3. Estimates of VE for the same intervals after vaccination during Omicron variant predominance were 52%, 38%, and 82%, respectively. During the period of Delta variant predominance, VE against laboratory-confirmed COVID-19-associated hospitalizations was 90% 14-179 days after dose 2, 81% ≥180 days after dose 2, and 94% ≥14 days after dose 3. During Omicron variant predominance, VE estimates for the same intervals after vaccination were 81%, 57%, and 90%, respectively. The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine. All unvaccinated persons should get vaccinated as soon as possible. All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.

Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data

Waning effectiveness of mRNA COVID-19 vaccines against inpatient and emergency department encounters

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024

Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa

Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >=50 years in Ontario, Canada

Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: a meta-regression

Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review

A Double Machine Learning Approach for the Evaluation of COVID-19 Vaccine Effectiveness under the Test-Negative Design: Analysis of Quebec Administrative Data

Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

Accelerate Vaccine Development Using Seamless Phase 2/3 Trial Designs

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study

TNDDR: Efficient and doubly robust estimation of COVID-19 vaccine effectiveness under the test-negative design

A novel approach for estimating vaccine efficacy for infections with multiple outcomes: application to a COVID-19 vaccine trial

Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN)

Correlates of improved outcomes in patients with COVID-19 treated in US emergency departments

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance